Compare Amphastar Pharmaceuticals Inc (AMPH) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

IEF trades at $93.63, down 0.09% on the day, with a bearish technical signal driven by moving averages. Recent news highlights bond market volatility amid shifting Fed rate expectations, with inflows into bond ETFs surging 60% year-over-year as of June 25, 2026 (CNBC). Dividend payments remain consistent, with the latest H1-26 payout at $0.32.

Outlook is cautious due to interest rate uncertainty; the Fed's potential hikes pose a headwind, but elevated demand for Treasury ETFs may provide support. Key risks include inflation persistence and geopolitical tensions impacting oil prices, as noted in Reuters and New York Post coverage on July 8, 2026.